What is GLP-1?

What is GLP-1?

GLP-1 is a hormone the body naturally produces to signal that food has arrived.

GLP-1 stands for glucagon-like peptide-1. It is a short chain of amino acids (longer, folded chains of amino acids are called proteins). Cells in the lining of the lower gut release the GLP-1 hormone into the bloodstream within minutes of eating.

A GLP-1 drug (e.g. Ozempic, Mounjaro, Wegovy; also called a GLP-1 receptor agonist) is an engineered version that mimics the naturally occurring hormone. The main difference is that the naturally occurring GLP-1 breaks down after a few minutes, but the engineered GLP-1 lasts about a week or so. The body is continuously being tricked into thinking that it already ate.

Naturally occurring vs. engineered

In a normal state, the natural GLP-1 hormone is destroyed within about two minutes. An enzyme in the blood called DPP-4 (which de-activates other peptides as well) removes the first two blocks of GLP-1, and the hormone is effectively silenced. The body does this because GLP-1 is supposed to be a signal, not a continuous state. Its job is to announce that a meal has arrived and then it switches off. A brief message that says “food just came in.”

A GLP-1 drug is engineered to make the signal last for a long time. It keeps the “recently fed” signal switched on continuously, so appetite stays low and blood sugar stays managed between meals and overnight.

The GLP-1 drug is engineered to last much longer in two main ways. First, it has a different building block where the DPP-4 enzyme typically makes a cut, so the enzyme can barely touch it. Second, it adds a fatty tail that grabs onto albumin (a common protein in blood), and the drug rides along albumin instead of being filtered out by the kidneys.

Exhibit 1A two-minute signal, rebuilt to last a week

What does it do once it’s released?

GLP-1 triggers the body and its organs to do what should be done after eating.

It tells the brain that food has arrived, which lowers appetite. It tells the stomach to empty slower and take its time digesting. It tells the pancreas to produce more insulin (only when blood sugar level is high) and produce less glucagon (which is a hormone that pushes blood sugar level up).

Exhibit 2Impact of GLP-1 to the body (highly simplified and illustrative)

Why does it cause weight loss?

GLP-1 drugs cause weight loss by turning hunger down and slowing the stomach, so people simply eat less.

The stomach empties more slowly at first, so meals feel bigger and last longer. Over the following weeks that effect fades, and the brain’s steady fullness signal does most of the lasting work. Eat less, and weight follows.

But as soon as you stop taking the medication, the weight tends to bounce right back. This is because the drug works by countering the impulse and desire to eat more. So when that goes away, the appetite returns.

How well does it work?

GLP-1 drugs led to weight loss of 15–20% over roughly 16 months (based on obesity clinical trials for semaglutide/Wegovy and tirzepatide/Zepbound).

Exhibit 3Weight loss percentage in GLP-1 clinical trials

What are the side effects and risks?

Nausea is the most frequent. Diarrhea, constipation, and vomiting were also cited, but less common. Notably, these side effects were mostly mild to moderate, largely from the impact of slowed digestion, which typically ease as the body adjusts.

In addition to the digestive effects, the rapid drop in weight itself is something to watch. Because the body goes through caloric deficit, the weight drops – which achieves the goal, but has to be managed well to be a healthy weight loss. You lose fat and some muscle in the process, so it is important to exercise throughout the treatment, so that the muscle loss is not harmful to the body. And because the weight loss can happen fast, it can lead to saggy skin and a hollowed-out appearance.

There are also uncommon but serious risks worth knowing. GLP-1 drugs carry a boxed warning – the FDA’s most serious – for thyroid C-cell tumors, so they are not used by people with a personal or family history of medullary thyroid cancer or MEN 2 (a rare inherited tumor syndrome). Other uncommon risks include pancreatitis and gallbladder problems, low blood sugar when combined with insulin or a sulfonylurea (an older diabetes pill), and slowed stomach emptying that can matter before surgery or anesthesia. GLP-1 drugs should not be used in pregnancy. As with any medication, this article is general education, not medical advice – whether one of these drugs is right for you is a conversation for a licensed clinician who knows your history, and it is always wise to do your own research.

Why is it usually a shot, not a pill?

The digestive system breaks peptides apart (that is its job). A GLP-1 peptide swallowed as a plain pill would be dismantled before it reached the blood, so injecting it under the skin, which skips the gut, is the most effective path. That is why the familiar versions are weekly shots.

Pills do exist. The semaglutide tablet (Rybelsus) comes with an absorption helper and must be taken on an empty stomach with a sip of water. Even then, only a trace gets in, so the pill holds far more drug than the shot.

Recent variations drop the peptide form altogether. Orforglipron (approved in April 2026 as Foundayo) is a small-molecule GLP-1 drug, sturdy enough to survive the gut on its own. It works as an ordinary daily pill, taken any time of day, with or without food. Foundayo pills are taken daily and have shown weight loss ranging between 8–12%.

What is next in GLP-1?

GLP-1 drugs began as a diabetes treatment – the first of its kind was approved in 2005. Then the weight-loss effect was becoming evident, and the first GLP-1 drug for obesity was approved in 2014.

The first GLP-1 drug for obesity (Saxenda/liraglutide) was a daily injection that led to ~8% body-weight loss. Then the breakthrough came when semaglutide – a more powerful molecule originally approved for type 2 diabetes as Ozempic – pivoted to treat obesity. Instead of daily injections, semaglutide is a weekly injection, and body-weight loss of 15–20% was substantially higher than the ~8% before. In June 2021, the FDA officially approved semaglutide for chronic weight management.

By early 2022, rumors of celebrities using Ozempic for rapid weight loss flooded TikTok and social media. On top of that influx of awareness and demand came manufacturing shortages and supply-chain challenges in 2022.

As the demand and success of GLP-1 drugs continued, scientists kept pushing for additional clinical studies to see what else the drug can treat. Below are some examples:

• Heart – in people who already had heart disease, semaglutide cut the risk of heart attack, stroke, and cardiovascular death by ~20% (FDA approved March 2024).
• Sleep apnea – tirzepatide treats obstructive sleep apnea (FDA approved December 2024).
• Kidney – semaglutide slows kidney disease in people with type 2 diabetes (FDA approved January 2025).
• Liver – semaglutide treats serious fatty-liver disease; an accelerated approval, with a confirming trial still to come (FDA approved August 2025).

GLP-1 receptors sit on tissues far beyond the pancreas – blood vessels, the heart’s pacemaker, parts of the kidney and brain. So the drugs can act on these organs through routes other than weight loss, which is why the heart and kidney benefits appear only partly explained by the weight loss.

Because GLP-1 also acts on the brain, it has been tested in neurodegenerative disease – but the big trials have largely disappointed. There are also studies in addiction, where the drugs appear to blunt cravings not just for food but for alcohol and nicotine. And because obesity itself drives many cancers, researchers are studying whether GLP-1 drugs modestly lower the risk of some cancers.

The molecules are evolving too. Semaglutide switches on the GLP-1 receptor alone; tirzepatide is a dual agonist – one molecule that also copies GIP, a second gut hormone released after a meal. Triple agonists and quadruple agonists – which add third and fourth hormones – are in development.

Exhibit 4Latest drugs add more active molecules

Takeaways

• GLP-1 is the body’s “food has arrived” signal. The drugs are engineered to mimic this signal.
• Naturally produced GLP-1 fades after a few minutes, but the engineered versions last about a week, which puts the body in a constant low-appetite state.
• These drugs were originally designed for diabetes, but now treat obesity, with weight-loss averages of 15–20%.
• Indications have recently expanded to sleep apnea and to heart, kidney, and liver disease – with more clinical trials underway.

General, educational, and informational research only, not tailored to your situation. Nothing here constitutes investment, legal, medical, or other professional advice; an offer to sell or a solicitation of an offer to buy any security; promotional or marketing material; or a recommendation. The author may hold positions in the securities or sectors discussed. Do your own research and consult a licensed professional. Full disclosures at www.eastrivernotes.com/disclosures.